| Abstrakt: |
The article reports on the ruling that the cancer drug Avastin (bevacizumab) should not be approved for the treatment of advanced breast cancer, according to an advisory panel to the U.S. Food and Drug Administration (FDA). The Genentech Inc., a biotechnology company that manufactures the drug, lost $10 to &66 as news of the decision broke out. In 2006, the European regulators had approved the drug for breast cancer, but the FDA stated that though it could aid some patients there was little evidence that it improved their long-term survival propects. |
